The Department of Health and Social Care (DHSC) has named Fiona Bride, currently Director of Medicines Value and Access at NHS England, as the interim director general for its commercial and growth directorate. This six-month secondment, during which she will also serve as acting chief commercial officer, is in effect until July 2026.
The appointment occurs as DHSC and the NHS undergo significant reform, including integrating functions into a unified structure. This transition aims to streamline commercial strategy, improve procurement, and strengthen industry partnerships to deliver efficiencies and innovation across the health and care system.
The commercial and growth directorate is a key executive division, central to overseeing commercial policy, supplier relationships, procurement strategy, and growth initiatives for the NHS's multi-billion-pound supply chain. Its responsibilities include contract negotiation, strategic partnerships, and ensuring commercial decisions deliver value for money while fostering health technology and service innovation.
Bride's interim role is part of a broader pattern of temporary placements as DHSC and NHS England move toward merger and the formation of a joint executive team, a process that began to solidify in late 2025. Numerous senior positions on this joint team have recently been filled by interims, even as permanent recruitment proceeds. Adding to this period of turnover, DHSC’s chief operating officer, Tom Riordan, is scheduled to depart at the end of February 2026.
DHSC has also brought in external expertise, such as a McKinsey partner for a joint DHSC/NHS England strategy role earlier this year.
Under Bride's interim leadership, the DHSC plans to continue efforts to optimise strategic supply arrangements, bolster the commercial capability of the health system, and ensure contracts align with wider policy goals like sustainability, innovation adoption, and cost containment.
Industry stakeholders, particularly the health technology sector, stress the importance of stability in commercial leadership during systemic reform. Clarity on procurement strategy and supplier engagement is vital as the NHS accelerates the adoption of digital tools, data platforms, and integrated service solutions. Commercial leadership is also crucial for managing large-scale technology contracts, engaging with small and medium-sized enterprises (SMEs), and integrating innovation into mainstream care pathways to ensure measurable improvements in outcomes and user experience.
